DK3325482T3 - Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater - Google Patents

Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater Download PDF

Info

Publication number: DK3325482T3
Authority: DK; Denmark
Prior art keywords: cytotoxic; preparation; methods; benzodiazepin; derivatives
Prior art date: 2015-07-21

Application number

DK16745598.9T

Other languages

English (en)

Inventor

Baudouin Gerard

Manami Shizuka

Michael Louis Miller

Richard A Silva

Original Assignee

Immunogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-21

Filing date

2016-07-21

Publication date

2020-09-28

2016-07-21 Application filed by Immunogen Inc filed Critical Immunogen Inc

2020-09-28 Application granted granted Critical

2020-09-28 Publication of DK3325482T3 publication Critical patent/DK3325482T3/da

Links

SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 title 1
231100000433 cytotoxic Toxicity 0.000 title 1
230000001472 cytotoxic effect Effects 0.000 title 1
0 CC(C)(*)CN(CCOCCOCCOC)c1cc(CO)cc(CO)c1 Chemical compound CC(C)(*)CN(CCOCCOCCOC)c1cc(CO)cc(CO)c1 0.000 description 19
ROVBYDCETXMZLN-UHFFFAOYSA-N COc(c(O)c1)cc2c1N=CC(Cc1c3cccc1)N3C2=O Chemical compound COc(c(O)c1)cc2c1N=CC(Cc1c3cccc1)N3C2=O ROVBYDCETXMZLN-UHFFFAOYSA-N 0.000 description 2
ROVBYDCETXMZLN-NSHDSACASA-N COc(c(O)c1)cc2c1N=C[C@H](Cc1c3cccc1)N3C2=O Chemical compound COc(c(O)c1)cc2c1N=C[C@H](Cc1c3cccc1)N3C2=O ROVBYDCETXMZLN-NSHDSACASA-N 0.000 description 2
WHOMMAJWTHZVJY-WRXSAAJRSA-N CC([C@H](C1)N2c3c1cccc3)Nc(cc(c(OC)c1)O)c1C2=O Chemical compound CC([C@H](C1)N2c3c1cccc3)Nc(cc(c(OC)c1)O)c1C2=O WHOMMAJWTHZVJY-WRXSAAJRSA-N 0.000 description 1
KJPKSKLKLWGIOS-UHFFFAOYSA-N COc(c(OCc1cc([N+]([O-])=O)cc(CO)c1)c1)cc(C(C2)=O)c1N=CC1C2c2ccccc2C1 Chemical compound COc(c(OCc1cc([N+]([O-])=O)cc(CO)c1)c1)cc(C(C2)=O)c1N=CC1C2c2ccccc2C1 KJPKSKLKLWGIOS-UHFFFAOYSA-N 0.000 description 1
DYPFZHNLKQOLFG-LXWOLXCRSA-N C[C@@H](C(N[C@@H](C)C(Nc1cc(CCl)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)=O)=O)NC(CCCCC(OC)=O)=O Chemical compound C[C@@H](C(N[C@@H](C)C(Nc1cc(CCl)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)=O)=O)NC(CCCCC(OC)=O)=O DYPFZHNLKQOLFG-LXWOLXCRSA-N 0.000 description 1
MYVRXOUKNZBDNS-UWVGGRQHSA-N C[C@@H](C(N[C@@H](C)C(Nc1cc(CO)cc(CO)c1)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C)C(Nc1cc(CO)cc(CO)c1)=O)=O)NC MYVRXOUKNZBDNS-UWVGGRQHSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
- C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pyridine Compounds (AREA)

DK16745598.9T 2015-07-21 2016-07-21 Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater DK3325482T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562195023P	2015-07-21	2015-07-21
US201662327973P	2016-04-26	2016-04-26
PCT/US2016/043414 WO2017015502A1 (en)	2015-07-21	2016-07-21	Methods of preparing cytotoxic benzodiazepine derivatives

Publications (1)

Publication Number	Publication Date
DK3325482T3 true DK3325482T3 (da)	2020-09-28

Family

ID=56557925

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK16745598.9T DK3325482T3 (da)	2015-07-21	2016-07-21	Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater
DK16745961.9T DK3325483T3 (da)	2015-07-21	2016-07-21	Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK16745961.9T DK3325483T3 (da)	2015-07-21	2016-07-21	Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater

Country Status (23)

Country	Link
US (11)	US10081640B2 (da)
EP (7)	EP3778602B1 (da)
JP (8)	JP6858745B2 (da)
KR (5)	KR20240055894A (da)
CN (5)	CN113087763A (da)
AU (7)	AU2016297087B2 (da)
CA (4)	CA2992082A1 (da)
CY (2)	CY1122553T1 (da)
DK (2)	DK3325482T3 (da)
ES (4)	ES2764548T3 (da)
HK (1)	HK1252322A1 (da)
HR (1)	HRP20201479T1 (da)
HU (1)	HUE051541T2 (da)
IL (10)	IL283355B (da)
LT (2)	LT3325483T (da)
PL (2)	PL3325482T3 (da)
PT (2)	PT3325482T (da)
RS (2)	RS60840B1 (da)
RU (3)	RU2746322C2 (da)
SG (2)	SG10202106529XA (da)
SI (2)	SI3325483T1 (da)
SM (2)	SMT202000004T1 (da)
WO (3)	WO2017015496A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL283355B (en)	2015-07-21	2022-08-01	Immunogen Inc	Methods for the preparation of cytotoxic benzodiazepine compounds
US12131907B2 (en)	2016-03-22	2024-10-29	Ev Group E. Thallner Gmbh	Device and method for bonding of substrates
AU2017345454B2 (en)	2016-10-19	2024-10-31	Invenra Inc.	Antibody constructs
BR112019013107A2 (pt)	2016-12-22	2019-12-17	Università Degli Studi Magna Graecia Catanzaro	anticorpos, molécula de ligação, receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, linfócito, ácido nucleico, célula de hibridoma, método para a produção do anticorpo monoclonal e usos
SI3573948T1 (sl) *	2017-01-25	2023-03-31	Immunogen, Inc.	Postopki za pripravo citotoksičnih derivatov benzodiazepina
IL322895A (en)	2018-06-05	2025-10-01	King S College London	Btnl3/8-targeted constructs for delivery of cargo to the digestive system
US10913713B2 (en) *	2018-11-12	2021-02-09	Immunogen, Inc.	Methods of preparing cytotoxic benzodiazepine derivatives
EP3880681B1 (en)	2018-11-12	2024-03-13	ImmunoGen, Inc.	Methods of preparing cytotoxic benzodiazepine derivatives
CN113661172A (zh) *	2019-03-29	2021-11-16	伊缪诺金公司	用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
AU2023298568A1 (en)	2022-06-30	2025-01-09	Toray Industries, Inc.	Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3763183A (en)	1972-07-10	1973-10-02	Sterling Drug Inc	1,2,3,10,11,11a-hexahydro-5h-pyrrolo (2,1-c)(1,4)benzodiazepines
US3860600A (en)	1972-07-10	1975-01-14	Sterling Drug Inc	Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines
US4678784A (en)	1984-04-11	1987-07-07	Mcneilab, Inc.	Method for the treatment of LHRH diseases and conditions
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9205051D0 (en)	1992-03-09	1992-04-22	Cancer Res Campaign Tech	Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them
CA2076465C (en)	1992-03-25	2002-11-26	Ravi V. J. Chari	Cell binding agent conjugates of analogues and derivatives of cc-1065
GB9818731D0 (en)	1998-08-27	1998-10-21	Univ Portsmouth	Compounds
EP1413582B1 (en)	1998-08-27	2006-03-15	Spirogen Limited	Dimeric pyrrolobenzodiazepines
AU765588C (en)	1999-11-24	2004-12-16	Immunogen, Inc.	Cytotoxic agents comprising taxanes and their therapeutic use
US6548042B2 (en) *	2000-08-07	2003-04-15	Arstad Erik	Bis-phosphonate compounds
UA75093C2 (en) *	2000-10-06	2006-03-15	Dimensional Pharm Inc	Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
US6441163B1 (en)	2001-05-31	2002-08-27	Immunogen, Inc.	Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en)	2001-12-21	2004-04-06	Immunogen Inc.	Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en)	2002-04-05	2004-06-29	Immunogen, Inc.	Prodrugs of CC-1065 analogs
AU2003247587B2 (en)	2002-08-02	2009-07-09	Immunogen, Inc.	Cytotoxic agents containing novel potent taxanes and their therapeutic use
JP2006500364A (ja)	2002-08-16	2006-01-05	イムノージェンインコーポレーテッド	高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
WO2004087716A1 (en)	2003-03-31	2004-10-14	Council Of Scientific And Industrial Research	Pyrrolo[(2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
RU2338747C2 (ru)	2003-03-31	2008-11-20	Каунсил Оф Сайентифик Энд Индастриал Рисерч	ДИМЕРЫ ПИРРОЛО [2, 1-c][1, 4] БЕНЗОДИАЗЕПИНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
RU2314309C2 (ru)	2003-03-31	2008-01-10	Каунсил Оф Сайентифик Энд Индастриал Рисерч	Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе
EP1608664B1 (en)	2003-03-31	2009-01-28	Council of Scientific and Industrial Research	Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof
US8088387B2 (en)	2003-10-10	2012-01-03	Immunogen Inc.	Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en)	2003-05-20	2007-10-02	Immunogen Inc.	Cytotoxic agents comprising new maytansinoids
WO2005040170A2 (en)	2003-10-22	2005-05-06	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
AU2003300718A1 (en)	2003-12-31	2005-07-21	Council Of Scientific And Industrial Research	Process for preparing pyrrolo(2, 1-c) (1, 4) benzodiazepine hybrids
JP4909258B2 (ja) *	2004-03-01	2012-04-04	スピロゲンリミティッド	Ｃ２置換ピロロベンゾジアゼピン類を調製するための主要な中間体としての１１−ヒドロキシ−５Ｈ−ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−５−オン誘導体
GB0404578D0 (en)	2004-03-01	2004-04-07	Spirogen Ltd	Pyrrolobenzodiazepines
GB0410725D0 (en)	2004-05-13	2004-06-16	Spirogen Ltd	Pyrrolobenzodiazepine therapeutic agents
GB0412492D0 (en) *	2004-06-04	2004-07-07	Sterix Ltd	Compound
AU2006238686B2 (en)	2005-04-21	2011-10-06	Medimmune Limited	Pyrrolobenzodiazepines
GB0508084D0 (en) *	2005-04-21	2005-06-01	Spirogen Ltd	Pyrrolobenzodiazepines
EP1931671B1 (en)	2005-10-05	2009-04-08	Spirogen Limited	Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c][1, 4]benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
DE602006015861D1 (de) *	2005-12-21	2010-09-09	Abbott Lab	Antivirale verbindungen
PT1813614E (pt)	2006-01-25	2012-01-09	Sanofi Sa	Agentes citotóxicos compreendendo novos derivados de tomaimicina
GB2453402B (en)	2006-02-13	2010-12-22	Council Scient Ind Res	Novel bis-pyrrolo[2,1.-c] [1,4] benzodiazepine-anthraquinone conjugates and a process for the preparation thereof
BRPI0711249A2 (pt)	2006-05-30	2012-03-13	Genentech, Inc.	Anticorpos, polinucleotídeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar câncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fabricação
ES2435779T3 (es)	2007-07-19	2013-12-23	Sanofi	Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
WO2009016647A1 (en)	2007-08-01	2009-02-05	Council Of Scientific & Industrial Research	Pyrrolo [2,1-c][1, 4] benzodiazepine-glycoside prodrugs useful as a selective anti tumor agent
CA2722696C (en)	2008-04-30	2021-08-10	Immunogen, Inc.	Cross-linkers and their uses
AU2009243009B2 (en)	2008-04-30	2014-09-11	Immunogen, Inc	Potent conjugates and hydrophilic linkers
GB0819095D0 (en)	2008-10-17	2008-11-26	Spirogen Ltd	Pyrrolobenzodiazepines
GB0822260D0 (en) *	2008-12-05	2009-01-14	Merten Christoph	Assay
EP2383263B1 (en) *	2008-12-30	2014-04-16	Industry-academic Cooperation Foundation, Chosun University	Novel thiazolidinedione derivative and use thereof
CA2750519C (en) *	2009-02-05	2018-09-25	Immunogen, Inc.	Benzodiazepine derivatives
WO2010126551A1 (en)	2009-04-30	2010-11-04	Immunogen, Inc.	Potent conjugates and hydrophilic linkers
US8314250B2 (en) *	2009-11-24	2012-11-20	Hoffmann-La Roche Inc.	Sultam derivatives
US8633304B2 (en) *	2009-12-08	2014-01-21	Gifu University	Oligonucleotide derivative comprising an aromatic compound
US8962279B2 (en) *	2009-12-30	2015-02-24	Intel Corporation	Solid-phase chelators and electronic biosensors
HRP20171078T1 (hr) *	2010-02-11	2017-10-06	Celgene Corporation	Derivati arilmetoksi izoindolina i pripravci koji ih sadrže, te postupci njihove uporabe
MY197016A (en)	2010-02-24	2023-05-20	Immunogen Inc	Folate receptor 1 antibodies and immunoconjugates and uses thereof
CN107019804A (zh)	2010-04-15	2017-08-08	西雅图基因公司	靶向吡咯并苯并二氮杂卓结合物
TWI540136B (zh)	2010-04-15	2016-07-01	梅迪繆思有限公司	吡咯并苯并二氮呯及其共軛物
BR112012026410B8 (pt)	2010-04-15	2023-01-31	Spirogen Dev Sarl	Composto e conjugado de pirrolobenzodiazepinas e usos dos mesmos
SG191965A1 (en)	2011-02-15	2013-08-30	Immunogen Inc	Methods of preparation of conjugates
CN102234253B (zh) *	2011-06-02	2013-07-03	重庆莱美药业股份有限公司	一种制备非布索坦中间体的方法
WO2014031566A1 (en) *	2012-08-22	2014-02-27	Immunogen, Inc.	Cytotoxic benzodiazepine derivatives
CA2925129C (en) *	2013-10-04	2023-04-04	Novartis Ag	3' end caps for rnai agents for use in rna interference
CN104628772A (zh)	2013-11-07	2015-05-20	四川恒康发展有限责任公司	一种抗肿瘤前药及其激活剂、组合物和应用
CN103664896B (zh) *	2013-11-25	2016-03-02	济南精合医药科技有限公司	一种抗肿瘤分子靶向药物克里唑替尼的合成工艺方法
KR20240023671A (ko)	2014-09-03	2024-02-22	이뮤노젠 아이엔씨	세포독성 벤조다이아제핀 유도체
MA40415A (fr) *	2014-09-03	2016-03-10	Immunogen Inc	Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
TW201613930A (en)	2014-09-03	2016-04-16	Immunogen Inc	Cytotoxic benzodiazepine derivatives
IL283355B (en)	2015-07-21	2022-08-01	Immunogen Inc	Methods for the preparation of cytotoxic benzodiazepine compounds
DK3380525T3 (da) *	2015-11-25	2024-01-29	Immunogen Inc	Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf

2016
- 2016-07-21 IL IL283355A patent/IL283355B/en unknown
- 2016-07-21 HK HK18111602.7A patent/HK1252322A1/zh unknown
- 2016-07-21 AU AU2016297087A patent/AU2016297087B2/en not_active Ceased
- 2016-07-21 RU RU2018105609A patent/RU2746322C2/ru active
- 2016-07-21 CN CN202110366892.7A patent/CN113087763A/zh active Pending
- 2016-07-21 RS RS20201132A patent/RS60840B1/sr unknown
- 2016-07-21 CN CN201680051138.1A patent/CN108290895B/zh not_active Expired - Fee Related
- 2016-07-21 IL IL294651A patent/IL294651B2/en unknown
- 2016-07-21 KR KR1020247012816A patent/KR20240055894A/ko not_active Withdrawn
- 2016-07-21 LT LTEP16745961.9T patent/LT3325483T/lt unknown
- 2016-07-21 CA CA2992082A patent/CA2992082A1/en active Pending
- 2016-07-21 KR KR1020187003181A patent/KR102659706B1/ko active Active
- 2016-07-21 DK DK16745598.9T patent/DK3325482T3/da active
- 2016-07-21 EP EP20181645.1A patent/EP3778602B1/en active Active
- 2016-07-21 LT LTEP16745598.9T patent/LT3325482T/lt unknown
- 2016-07-21 EP EP22195446.4A patent/EP4163284A1/en not_active Withdrawn
- 2016-07-21 HU HUE16745598A patent/HUE051541T2/hu unknown
- 2016-07-21 RS RS20191647A patent/RS59806B1/sr unknown
- 2016-07-21 PL PL16745598T patent/PL3325482T3/pl unknown
- 2016-07-21 IL IL286788A patent/IL286788B2/en unknown
- 2016-07-21 RU RU2018105756A patent/RU2727151C2/ru active
- 2016-07-21 ES ES16745961T patent/ES2764548T3/es active Active
- 2016-07-21 WO PCT/US2016/043406 patent/WO2017015496A1/en not_active Ceased
- 2016-07-21 IL IL305989A patent/IL305989A/en unknown
- 2016-07-21 KR KR1020187005041A patent/KR102660070B1/ko active Active
- 2016-07-21 CN CN201680053120.5A patent/CN108055844A/zh active Pending
- 2016-07-21 CN CN201680053093.1A patent/CN108026103B/zh not_active Expired - Fee Related
- 2016-07-21 RU RU2018105752A patent/RU2018105752A/ru not_active Application Discontinuation
- 2016-07-21 SG SG10202106529XA patent/SG10202106529XA/en unknown
- 2016-07-21 PL PL16745961T patent/PL3325483T3/pl unknown
- 2016-07-21 EP EP23183947.3A patent/EP4286387A3/en not_active Withdrawn
- 2016-07-21 ES ES16745598T patent/ES2820358T3/es active Active
- 2016-07-21 ES ES20181645T patent/ES2959741T3/es active Active
- 2016-07-21 SI SI201630578T patent/SI3325483T1/sl unknown
- 2016-07-21 EP EP16745961.9A patent/EP3325483B1/en active Active
- 2016-07-21 PT PT167455989T patent/PT3325482T/pt unknown
- 2016-07-21 CA CA2991305A patent/CA2991305C/en active Active
- 2016-07-21 AU AU2016297608A patent/AU2016297608B2/en not_active Ceased
- 2016-07-21 CA CA3227588A patent/CA3227588A1/en active Pending
- 2016-07-21 AU AU2016297607A patent/AU2016297607A1/en not_active Abandoned
- 2016-07-21 JP JP2018502785A patent/JP6858745B2/ja not_active Expired - Fee Related
- 2016-07-21 IL IL305279A patent/IL305279A/en unknown
- 2016-07-21 EP EP16748205.8A patent/EP3325485B1/en active Active
- 2016-07-21 DK DK16745961.9T patent/DK3325483T3/da active
- 2016-07-21 PT PT167459619T patent/PT3325483T/pt unknown
- 2016-07-21 US US15/216,548 patent/US10081640B2/en active Active
- 2016-07-21 SG SG10202009354SA patent/SG10202009354SA/en unknown
- 2016-07-21 CN CN202110219412.4A patent/CN113004288A/zh active Pending
- 2016-07-21 ES ES19200626T patent/ES2933376T3/es active Active
- 2016-07-21 WO PCT/US2016/043402 patent/WO2017015495A1/en not_active Ceased
- 2016-07-21 SI SI201630923T patent/SI3325482T1/sl unknown
- 2016-07-21 US US15/216,512 patent/US9873708B2/en active Active
- 2016-07-21 EP EP16745598.9A patent/EP3325482B1/en active Active
- 2016-07-21 SM SM20200004T patent/SMT202000004T1/it unknown
- 2016-07-21 SM SM20200506T patent/SMT202000506T1/it unknown
- 2016-07-21 HR HRP20201479TT patent/HRP20201479T1/hr unknown
- 2016-07-21 JP JP2018502800A patent/JP2018522018A/ja not_active Withdrawn
- 2016-07-21 CA CA2991326A patent/CA2991326A1/en not_active Abandoned
- 2016-07-21 JP JP2018502791A patent/JP6787995B2/ja not_active Expired - Fee Related
- 2016-07-21 KR KR1020247012991A patent/KR20240055903A/ko not_active Withdrawn
- 2016-07-21 US US15/216,517 patent/US9890179B2/en not_active Expired - Fee Related
- 2016-07-21 KR KR1020187005040A patent/KR20180038460A/ko not_active Withdrawn
- 2016-07-21 EP EP19200626.0A patent/EP3653628B1/en active Active
- 2016-07-21 WO PCT/US2016/043414 patent/WO2017015502A1/en not_active Ceased
2017
- 2017-12-11 US US15/837,832 patent/US10370389B2/en active Active
2018
- 2018-01-03 US US15/860,864 patent/US10392407B2/en not_active Expired - Fee Related
- 2018-01-11 IL IL256854A patent/IL256854A/en unknown
- 2018-01-11 IL IL256860A patent/IL256860B/en active IP Right Grant
- 2018-01-11 IL IL256861A patent/IL256861B/en active IP Right Grant
- 2018-09-12 US US16/129,008 patent/US10899775B2/en active Active
2019
- 2019-06-06 US US16/433,117 patent/US10787463B2/en active Active
- 2019-06-21 US US16/448,261 patent/US20200017526A1/en not_active Abandoned
- 2019-12-30 CY CY20191101364T patent/CY1122553T1/el unknown
2020
- 2020-08-10 IL IL276631A patent/IL276631B/en unknown
- 2020-08-10 IL IL276630A patent/IL276630B/en active IP Right Grant
- 2020-08-12 US US16/991,700 patent/US11420982B2/en active Active
- 2020-09-23 CY CY20201100899T patent/CY1123390T1/el unknown
- 2020-10-28 JP JP2020180147A patent/JP6995178B2/ja not_active Expired - Fee Related
- 2020-11-23 US US17/101,942 patent/US20210171547A1/en not_active Abandoned
2021
- 2021-03-24 JP JP2021049502A patent/JP7337114B2/ja active Active
- 2021-04-20 AU AU2021202403A patent/AU2021202403B2/en not_active Ceased
- 2021-05-17 AU AU2021203148A patent/AU2021203148B2/en not_active Ceased
- 2021-12-14 JP JP2021202215A patent/JP7334228B2/ja active Active
2022
- 2022-12-14 US US18/080,973 patent/US20230257400A1/en not_active Abandoned
2023
- 2023-03-03 AU AU2023201339A patent/AU2023201339A1/en not_active Abandoned
- 2023-04-11 AU AU2023202221A patent/AU2023202221A1/en not_active Abandoned
- 2023-08-16 JP JP2023132536A patent/JP2023162264A/ja not_active Withdrawn
- 2023-08-22 JP JP2023134420A patent/JP2023166434A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
US20190112320A1 (en)	2019-04-18
AU2021202403B2 (en)	2022-12-08
CA3227588A1 (en)	2017-01-26
LT3325483T (lt)	2020-01-27
PL3325482T3 (pl)	2021-01-11
RU2018105752A (ru)	2019-08-21
US11420982B2 (en)	2022-08-23
IL286788B1 (en)	2023-09-01
EP4163284A1 (en)	2023-04-12
CN108026103A (zh)	2018-05-11
CA2992082A1 (en)	2017-01-26
US20200017526A1 (en)	2020-01-16
SI3325483T1 (sl)	2020-03-31
EP3325485A1 (en)	2018-05-30
AU2016297087A1 (en)	2018-02-08
US10899775B2 (en)	2021-01-26
ES2764548T3 (es)	2020-06-03
US20170050985A1 (en)	2017-02-23
RU2018105609A3 (da)	2020-04-30
US9890179B2 (en)	2018-02-13
WO2017015495A1 (en)	2017-01-26
HK1252322A1 (zh)	2019-05-24
US20170050986A1 (en)	2017-02-23
IL256861A (en)	2018-03-29
US20180201626A1 (en)	2018-07-19
CY1122553T1 (el)	2021-01-27
EP4286387A2 (en)	2023-12-06
KR102659706B1 (ko)	2024-04-23
IL276631A (en)	2020-09-30
IL276630B (en)	2021-06-30
EP3653628A1 (en)	2020-05-20
HK1252323A1 (en)	2019-05-24
IL276630A (en)	2020-09-30
US20210171547A1 (en)	2021-06-10
JP7337114B2 (ja)	2023-09-01
RU2018105609A (ru)	2019-08-26
IL256854A (en)	2018-03-29
AU2016297607A1 (en)	2018-02-08
US20230257400A1 (en)	2023-08-17
EP3325482A1 (en)	2018-05-30
CA2991305A1 (en)	2017-01-26
AU2021202403A1 (en)	2021-05-20
JP2018522018A (ja)	2018-08-09
KR102660070B1 (ko)	2024-04-24
RU2727151C2 (ru)	2020-07-21
IL283355B (en)	2022-08-01
US10370389B2 (en)	2019-08-06
US10787463B2 (en)	2020-09-29
RU2018105756A (ru)	2019-08-21
IL283355A (en)	2021-07-29
WO2017015502A1 (en)	2017-01-26
LT3325482T (lt)	2020-11-25
AU2021203148A1 (en)	2021-06-10
SMT202000506T1 (it)	2020-11-10
IL286788B2 (en)	2024-01-01
RS59806B1 (sr)	2020-02-28
SG10202009354SA (en)	2020-11-27
JP6787995B2 (ja)	2020-11-18
PT3325483T (pt)	2020-01-15
AU2023202221A1 (en)	2023-05-04
CN113087763A (zh)	2021-07-09
AU2021203148B2 (en)	2023-01-12
AU2016297608A1 (en)	2018-02-08
US20210171546A1 (en)	2021-06-10
HUE051541T2 (hu)	2021-03-01
RU2018105752A3 (da)	2019-12-30
WO2017015502A8 (en)	2017-03-02
CN108055844A (zh)	2018-05-18
US20170051011A1 (en)	2017-02-23
JP6995178B2 (ja)	2022-02-21
EP3778602B1 (en)	2023-07-12
IL276631B (en)	2021-10-31
IL294651B2 (en)	2024-02-01
CN108290895A (zh)	2018-07-17
KR20240055894A (ko)	2024-04-29
EP3778602A1 (en)	2021-02-17
CN108290895B (zh)	2021-03-19
HK1252321A1 (en)	2019-05-24
JP7334228B2 (ja)	2023-08-28
JP2021035958A (ja)	2021-03-04
RU2018105756A3 (da)	2019-12-23
JP2022046542A (ja)	2022-03-23
RU2746322C2 (ru)	2021-04-12
JP2023166434A (ja)	2023-11-21
DK3325483T3 (da)	2020-01-20
EP3325482B1 (en)	2020-06-24
CA2991305C (en)	2024-03-12
EP3653628B1 (en)	2022-09-14
EP3325485B1 (en)	2020-04-08
US9873708B2 (en)	2018-01-23
JP2021100959A (ja)	2021-07-08
EP3325483B1 (en)	2019-10-02
SI3325482T1 (sl)	2020-11-30
IL256860A (en)	2018-03-29
IL305279A (en)	2023-10-01
IL294651B1 (en)	2023-10-01
PT3325482T (pt)	2020-09-24
KR20180038460A (ko)	2018-04-16
IL305989A (en)	2023-11-01
IL256860B (en)	2020-08-31
CN108026103B (zh)	2021-04-16
JP6858745B2 (ja)	2021-04-14
JP2018524387A (ja)	2018-08-30
JP2023162264A (ja)	2023-11-08
SMT202000004T1 (it)	2020-03-13
HRP20201479T1 (hr)	2020-12-11
KR20180038461A (ko)	2018-04-16
CY1123390T1 (el)	2022-03-24
ES2820358T3 (es)	2021-04-20
AU2023201339A1 (en)	2023-04-06
IL286788A (en)	2021-10-31
EP4286387A3 (en)	2024-02-21
IL294651A (en)	2022-09-01
AU2016297608B2 (en)	2021-02-18
ES2959741T3 (es)	2024-02-28
SG10202106529XA (en)	2021-07-29
CN113004288A (zh)	2021-06-22
KR20180026741A (ko)	2018-03-13
WO2017015496A1 (en)	2017-01-26
IL256861B (en)	2020-08-31
JP2018526340A (ja)	2018-09-13
US10392407B2 (en)	2019-08-27
US20190389883A1 (en)	2019-12-26
RS60840B1 (sr)	2020-10-30
AU2016297087B2 (en)	2021-02-18
ES2933376T3 (es)	2023-02-06
US10081640B2 (en)	2018-09-25
PL3325483T3 (pl)	2020-05-18
US20190010169A1 (en)	2019-01-10
CA2991326A1 (en)	2017-01-26
KR20240055903A (ko)	2024-04-29
EP3325483A1 (en)	2018-05-30

Publication	Publication Date	Title
DK3096741T3 (da)	2020-09-28	Fremgangsmåde til fremstillingen af hybridosomer
DK3192902T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3174858T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af pyrazoler
DK3189056T3 (da)	2020-09-14	Cytotoksiske benzodiazepinderivater
IL264143B (en)	2021-10-31	Processes for preparing olaparib
DK3325443T3 (da)	2022-07-18	Fremgangsmåde til fremstilling af pridopidin
DK3325482T3 (da)	2020-09-28	Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater
DK3390390T3 (da)	2021-12-06	Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3237045T3 (da)	2021-05-10	Indretning til indgivelse af lægemidler
DK3186244T3 (da)	2020-07-13	Dioxolananaloger af uridin til behandling af cancer
DK3233813T3 (da)	2022-03-07	Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3204398T3 (da)	2020-06-02	Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer
HUE050974T2 (hu)	2021-01-28	Eljárás pirimidinszulfamid-származékok elõállítására
DK3383436T3 (da)	2023-11-20	Forbedret fremgangsmåde til fremstilling af indocyaningrønt
DK3191406T3 (da)	2021-02-08	Fremgangsmåde til fremstilling af aluminiumchloridderivater
DK3280408T3 (da)	2020-02-03	Fremgangsmåde til fremstilling af dicycloplatin
DK3166611T3 (da)	2020-12-07	Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxypicolinsyrer
DK3418273T3 (da)	2022-03-21	Derivater af flavagliner
IL287119B1 (en)	2023-03-01	Bryostatin compounds and methods of preparing the same
DK3274143T3 (da)	2019-11-25	Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3573948T3 (da)	2023-01-09	Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater
DK3120153T3 (da)	2020-11-09	Cellulær-baseret fremgangsmåde til bestemmelse af muligheden for defibrotid
DK3020358T3 (da)	2019-12-16	Fremgangsmåde til fremstilling af tandprotese
DK3148993T3 (da)	2019-05-20	Fremgangsmåde til fremstilling af thiazolderivater
DK3500572T3 (da)	2022-12-19	Cytisinderivater til behandling af afhængighed